Myomo (MYO) Expected to Announce Quarterly Earnings on Monday

Myomo (NYSEAMERICAN:MYO) is projected to release its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $10.4030 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

Myomo Stock Performance

Shares of MYO stock opened at $0.80 on Friday. The business’s 50 day simple moving average is $0.87 and its 200 day simple moving average is $0.93. Myomo has a one year low of $0.64 and a one year high of $6.30. The stock has a market capitalization of $30.75 million, a PE ratio of -2.76 and a beta of 1.17. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.49 and a quick ratio of 2.10.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets dropped their price target on shares of Myomo from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $7.67.

Institutional Investors Weigh In On Myomo

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rosalind Advisors Inc. grew its stake in Myomo by 1.3% during the fourth quarter. Rosalind Advisors Inc. now owns 3,839,772 shares of the company’s stock worth $3,494,000 after purchasing an additional 48,984 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Myomo by 160.8% during the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock worth $1,446,000 after buying an additional 412,631 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Myomo by 47.8% during the 4th quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock worth $395,000 after buying an additional 140,427 shares during the period. State Street Corp grew its position in shares of Myomo by 5.1% during the 4th quarter. State Street Corp now owns 399,853 shares of the company’s stock worth $364,000 after buying an additional 19,563 shares during the period. Finally, Nuveen LLC increased its stake in shares of Myomo by 66.4% in the 4th quarter. Nuveen LLC now owns 370,325 shares of the company’s stock valued at $337,000 after acquiring an additional 147,784 shares in the last quarter. Institutional investors own 44.99% of the company’s stock.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.